Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer

Zhaohui Jin, Frank A. Sinicrope

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide. Universal MMR/MSI testing is standard of care for all patients with newly diagnosed CRC based on multi-society guidelines in the United States. Such testing is intended to identify patients with Lynch Syndrome due to a germline mutation in an MMR gene, but also detects those with sporadic dMMR/MSI-high CRCs. The prognostic utility of MMR/MSI status in non-metastatic colorectal cancer has been studied extensively, yet more limited data are available for its predictive utility. Results have not been entirely consistent due to potential stage-related differences and limited numbers of dMMR/MSI-H patients included in the studies. In this review, we summarize the current evidence for the prognostic and predictive value of dMMR/MSI-H in non-metastatic CRC, and discuss the use of this biomarker for patient management and treatment decisions in clinical practice.

Original languageEnglish (US)
Article number300
Pages (from-to)1-16
Number of pages16
Issue number2
StatePublished - Jan 2 2021


  • Microsatellite instability
  • Mismatch repair deficiency
  • Non-metastatic colorectal cancer
  • Predictive
  • Prognostic

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prognostic and predictive values of mismatch repair deficiency in non-metastatic colorectal cancer'. Together they form a unique fingerprint.

Cite this